Psoriasis Treatment Selection: Route of Administration and Comparative Effectiveness

Moderate to severe psoriasis management has undergone a substantive shift with the arrival of icotrakinra, the first oral IL-23 receptor blocker, alongside the continued maturation of advanced biologic therapies targeting the IL-23/IL-17 axis. In this HCP Live special report, Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine, examines how clinicians can navigate treatment selection among biologics and emerging oral agents by integrating mechanism-based sequencing, indirect comparative effectiveness data, long-term durability evidence, and individualized patient factors including psoriatic arthritis pattern and comorbidity profile.